Argue your case. Share evidence. Stay open to being wrong. Votes reflect opinions, not verified truth.
Should people be allowed to patent parts of the human genome? Ownership can encourage investment, but naturally occurring biology raises different questions from invention.
Should pharmaceutical companies have to disclose the full cost of developing a drug? Transparency may inform pricing debates while exposing information competitors could exploit.
Should lifesaving medicines be exempt from patent protection? Access and affordability compete with incentives to finance difficult and uncertain research.
Should private companies own patents on discoveries funded by taxpayers? Commercial incentives can support development, but public investment creates a claim to shared benefits.
Should major scientific claims require independent replication before media coverage? Caution protects readers while potentially delaying discussion of important emerging findings.
Should scientific journals publish every failed replication attempt? Negative results can correct the record, but quality control remains necessary for fair evaluation.
Should researchers lose funding for repeatedly exaggerating findings? Strong accountability could discourage hype while requiring fair distinctions between error and deliberate distorti… See more
Should scientific results ever be withheld from the public for security reasons? Open knowledge supports scrutiny, while some information can also enable serious harm.
Should governments ban research that could create unusually dangerous pathogens? Risk prevention can conflict with knowledge needed to understand and prepare for natural threats.
Should research on more intelligent animals face stricter limits? Different capacities may matter ethically, but intelligence is not a simple measure of suffering.
Should animals be used in research when no alternative exists? Potential human benefits must be weighed against suffering imposed on beings unable to consent.
Should healthy volunteers be paid large sums for risky medical studies? Compensation recognizes burden, but financial pressure may undermine genuinely voluntary participation.
